OverviewSuggest Edit

Amgen (formerly known as Applied Molecular Genetics) is a biotech company discovering, developing, manufacturing, and delivering human therapeutics products. It focuses on oncology and hematology, cardiovascular, inflammation, bone health, and neuroscience diseases. Its major brands include:

TypePublic
Founded1980
HQThousand Oaks, US
Websiteamgen.com
Employee Ratings3.8
Overall CultureC-

Latest Updates

Employees (est.) (Dec 2019)23,400(+9%)
Job Openings398
Revenue (FY, 2019)$23.4 B(-1%)
Share Price (Nov 2020)$237.1 (-1%)
Cybersecurity ratingBMore

Key People/Management at Amgen

Robert A. Bradway

Robert A. Bradway

Chairman and Chief Executive Officer
Christophe Bourdon

Christophe Bourdon

Senior Vice President, General Manager, U.S. Oncology Business
Victoria H. Blatter

Victoria H. Blatter

Senior Vice President, U.S. Government Affairs
Judy Gawlik Brown

Judy Gawlik Brown

Senior Vice President, Corporate Affairs
Tia Bush

Tia Bush

Senior Vice President, Quality
Raymond Deshaies

Raymond Deshaies

Senior Vice President, Global Research
Show more

Amgen Office Locations

Amgen has offices in Thousand Oaks, Cambridge, Louisville, South San Francisco and in 57 other locations
Thousand Oaks, US (HQ)
1 Amgen Center Dr
Cambridge, US
360 Binney St
Louisville, US
12000 Plantside Dr
South San Francisco, US
1120 Veterans Blvd
Tampa, US
2202 N Westshore Blvd
Washington, US
601 13th St NW 12th Floor
Show all (65)

Amgen Financials and Metrics

Amgen Revenue

Embed Graph
View revenue for all periods
Amgen's revenue was reported to be $23.36 b in FY, 2019 which is a 1.6% decrease from the previous period.
USD

Revenue (Q3, 2020)

6.1b

Market capitalization (12-Nov-2020)

138.1b

Closing stock price (12-Nov-2020)

237.1

Cash (30-Sept-2020)

9.1b

EV

163.3b
Amgen's current market capitalization is $138.1 b.
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Revenue

23.0b22.8b23.7b23.4b

Revenue growth, %

6%(1%)4%(2%)

Cost of goods sold

4.2b4.1b4.1b4.4b

Gross profit

18.8b18.8b19.6b19.0b
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

5.5b5.8b5.8b5.6b6.1b5.9b5.6b5.9b5.7b6.2b5.9b6.1b

Cost of goods sold

996.0m1.0b990.0m944.0m1.0b1.0b1.1b1.0b1.0b1.5b

Gross profit

4.5b4.8b4.8b4.6b5.0b4.9b4.5b4.9b4.7b4.6b

Gross profit Margin, %

82%82%83%83%83%82%81%83%82%75%
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Cash

3.2b3.8b6.9b6.0b

Accounts Receivable

3.2b3.2b3.6b4.1b

Inventories

2.7b2.8b2.9b3.6b

Current Assets

46.0b49.5b37.6b18.4b
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

3.4b2.6b3.0b9.7b10.1b12.0b7.4b5.5b11.4b7.7b9.1b9.1b

Accounts Receivable

3.2b3.6b3.4b3.6b3.5b3.4b3.8b3.8b3.6b5.0b5.4b4.1b

Inventories

2.9b3.0b2.9b3.0b3.1b3.0b3.0b3.2b3.2b3.7b3.8b3.9b

Current Assets

46.5b48.4b49.8b40.7b38.0b38.3b35.2b30.7b31.1b18.8b22.9b22.7b
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Net Income

7.7b2.0b8.4b7.8b

Depreciation and Amortization

2.1b2.0b1.9b2.2b

Inventories

(80.0m)133.0m(3.0m)(66.0m)

Accounts Payable

(44.0m)424.0m(143.0m)164.0m
USDFY, 2016

Revenue/Employee

1.2m

Debt/Equity

1.2 x

Debt/Assets

0.4 x

Financial Leverage

2.6 x
Show all financial metrics

Amgen Operating Metrics

Feb, 2016FY, 2016Feb, 2017FY, 2017Feb, 2018FY, 2018Feb, 2019FY, 2019Feb, 2020

Countries

100 100 100 100

Facilities

190 180 190 190

Patents (US)

22 22 27 34

Phase III Trials Products

15 12 15 11 13 7 8 10 14
Show all operating metrics

Amgen Acquisitions / Subsidiaries

Company NameDateDeal Size
OtezlaNovember 19, 2019$13.40 b
NuevolutionMay 22, 2019
CatherexDecember 21, 2015
Dezima PharmaSeptember 16, 2015$300 m
Onyx PharmaceuticalsAugust 24, 2013$10.50 b
DeCODE GeneticsDecember 10, 2012$415 m
MN PharmaceuticalsApril 26, 2012$700 m
KAI PharmaceuticalsApril 10, 2012$315 m
MicrometJanuary 26, 2012
BergamoApril 08, 2011
Show more

Amgen Revenue Breakdown

Embed Graph

Amgen revenue breakdown by geographic segment: 25.5% from Rest of World and 74.5% from United States

Amgen Cybersecurity Score

Cybersecurity ratingPremium dataset

B

83/100

SecurityScorecard logo

Amgen Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

50-59

out of 100

CSRHub logo

Amgen Online and Social Media Presence

Embed Graph

Amgen Company Culture

  • Overall Culture

    C-

    62/100

  • CEO Rating

    D+

    62/100

  • Compensation

    B+

    74/100

  • Diversity

    D

    53/100

Learn more on Comparably

Amgen News and Updates

Colorectal Cancer Market is Expected to Grow at a CAGR of 3.5% in 2020-2027 with Top key players Epigenomics AG, Novigenix SA, Volitionrx Limited, Abbott Laboratories, Amgen Inc.

Europe, the colorectal cancer market, is anticipated to reach US$ 5,573.2 Mn in 2027 from US$ 4,241.2 Mn in 2019. The market is projected to grow with a CAGR of 3.5% from 2020-2027. Posted via Industry Today. Follow us on Twitter @IndustryToday

: Amgen stock rises after earnings beat

Amgen Inc. AMGN shares rose in the extended session Wednesday after the biotech drug maker topped Wall Street estimates for the quarter. Amgen shares advanced 1.2% after hours, following a 3.2% decline in the regular session to close at $216.38. The company reported third-quarter net income of $2.02…

Amgen, Cytokinetics and Servier Announce Topline Results From GALACTIC-HF, a Phase 3 Trial of Omecamtiv Mecarbil in Patients With Heart Failure

Trial Met Primary Composite Endpoint of Reduction in Cardiovascular Death or Heart Failure Events 

Amgen Announces Five-Year Data That Reinforce The Safety And Efficacy Profile Of Aimovig® (erenumab-aooe) In Adult Patients With Episodic Migraine

THOUSAND OAKS, Calif., Oct. 3, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that results reinforcing the long-term safety and efficacy profile of Aimovig® (erenumab-aooe) in patients with episodic migraine (EM) are being presented at the Migraine Trust Virtual Symposium....

Insights on the Auto-Injectors Global Market to 2026 - Featuring Antares Pharma, Mylan & Amgen Among Others

Dublin, Oct. 01, 2020 (GLOBE NEWSWIRE) -- The "Auto-Injectors Market Global Forecast by Regions, Application (Anaphylaxis, Multiple Sclerosis, Rheumatoid Arthritis, Others), Product Types, Distribution Channels, Company Analysis" report has been added to ResearchAndMarkets.com's offering. This rep…

Clinical Trials Management System 2020 Global Market Key Players – Novo Nordisk, Amgen, Pfizer, Roche - Analysis and Forecast to 2026

Wiseguyreports.Com Publish New Market Research Report On-“Clinical Trials Management System Market 2020 Global Analysis, Size, Share, Trends, Opportunities and Growth, Forecast 2026” Posted via Industry Today. Follow us on Twitter @IndustryToday
Show more

Amgen Frequently Asked Questions

  • When was Amgen founded?

    Amgen was founded in 1980.

  • Who are Amgen key executives?

    Amgen's key executives are Robert A. Bradway, Christophe Bourdon and Victoria H. Blatter.

  • How many employees does Amgen have?

    Amgen has 23,400 employees.

  • What is Amgen revenue?

    Latest Amgen annual revenue is $23.4 b.

  • What is Amgen revenue per employee?

    Latest Amgen revenue per employee is $998.4 k.

  • Who are Amgen competitors?

    Competitors of Amgen include Biogen, Avantor and Hospira.

  • Where is Amgen headquarters?

    Amgen headquarters is located at 1 Amgen Center Dr, Thousand Oaks.

  • Where are Amgen offices?

    Amgen has offices in Thousand Oaks, Cambridge, Louisville, South San Francisco and in 57 other locations.

  • How many offices does Amgen have?

    Amgen has 65 offices.